anastrozole has been researched along with aromasil in 239 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.26) | 18.2507 |
| 2000's | 118 (49.37) | 29.6817 |
| 2010's | 106 (44.35) | 24.3611 |
| 2020's | 12 (5.02) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, JZ; Khan, MZI; Nazli, A; Uzair, M | 1 |
| Blijham, GH; de Jong, PC | 1 |
| Bonneterre, J; Feutrie, ML | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N | 1 |
| Perey, L | 1 |
| Sonoo, H | 1 |
| Attolico, M; Crucitta, E; De Lena, M; Lorusso, V; Mazzei, A; Sambiasi, D | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Auvray, P; Bichat, F; Genne, P | 1 |
| de Crémoux, P | 1 |
| Kerbrat, P; Lefeuvre, C | 1 |
| Hamilton, A; Volm, M | 1 |
| Buzdar, A; Howell, A | 1 |
| Lønning, PE | 1 |
| Murray, R | 1 |
| Nabholtz, JM; Reese, DM | 1 |
| Bando, H; Saji, S; Toi, M | 1 |
| Dixon, JM; Miller, WR | 1 |
| Buzdar, AU | 6 |
| Junker, A; Possinger, K; Wiedemann, GJ | 1 |
| Buzdar, A; Johnson, PE | 1 |
| Goss, PE | 1 |
| Soudon, J | 1 |
| Jones, SE | 1 |
| Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R | 1 |
| Ingle, JN | 4 |
| Goss, PE; Smith, RE | 1 |
| Assikis, VJ; Buzdar, A | 1 |
| Buzdar, AU; Eiermann, W; Nabholtz, JM; Robertson, JF | 1 |
| Robertson, JF | 1 |
| Baum, M; Buzdar, A | 1 |
| Rocchi, A; Verma, S | 1 |
| Rose, C | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Eckhardt, S | 1 |
| Gershanovich, M; Mouridsen, H | 1 |
| Domont, J; Khayat, D; Namer, M; Spano, JP | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Campos, SM | 1 |
| Arora, A; Potter, JF | 1 |
| Clemons, M; Coleman, RE; Verma, S | 1 |
| Sainsbury, R | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Abou-Jawde, RM; Alemany, CA; Budd, GT; Choueiri, TK | 1 |
| Bessho, T; Hirai, I; Kinoshita, T; Kokawa, Y; Nishida, M; Nishimura, O; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yokochi, H; Yoshimas, T | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Fentiman, IS | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Clemons, MJ; Freedman, OC; Verma, S | 2 |
| Michaud, LB | 1 |
| Mouridsen, HT | 1 |
| Kaplow, R | 1 |
| Jakesz, R | 1 |
| Geisler, J; Lønning, PE | 3 |
| Caraglia, M; Cigolari, S; Colucci, G; Del Prete, S; Fanelli, F; Febbraro, A; Ferrari, E; Formato, R; Gebbia, V; Giotta, G; Iaffaioli, RV; Ianniello, G; Incoronato, P; Manzione, L; Marano, O; Marzano, N; Nasti, G; Pappagallo, G; Pedicini, T; Pezzella, G; Pisano, A; Pisconti, S; Pizza, C; Quattrin, S; Tortoriello, A | 1 |
| Delozier, T; Khayat, D; Spano, JP | 1 |
| Dodwell, D; Vergote, I | 1 |
| Ingle, JN; Suman, VJ | 1 |
| Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S | 1 |
| Chowdhury, S; Ellis, PA | 1 |
| Jiang, ZF; Song, ST | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Dowsett, M; Johnston, SR; Martin, LA | 1 |
| Abram, P; Vergote, I | 1 |
| Howell, A; Locker, GY | 1 |
| Mouridsen, HT; Robert, NJ | 1 |
| Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F | 1 |
| Shan, ZZ; Shen, KW; Wang, LP | 1 |
| Gltick, S | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Grana, G | 1 |
| Geyer, H; Guddat, S; Haenelt, N; Koch, A; Kohler, M; Mareck, U; Opfermann, G; Schänzer, W; Thevis, M | 1 |
| Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Giordano, SH; Hortobagyi, GN | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 2 |
| Brueggemeier, RW | 1 |
| Chien, AJ; Goss, PE | 1 |
| Chu, QD; Li, BD; McDonald, JC | 1 |
| Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Yoshida, Y | 1 |
| Ellis, MJ; Rigden, CE | 1 |
| Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Lian, ZQ; Yang, MT | 1 |
| Hou, KY; Ji, JF; Jia, TZ; Li, HP; Wang, MP; Wang, YF; Xiao, Y; Zhao, HM | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Alimonti, A; Bria, E; Carlini, P; Cognetti, F; Cresti, N; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Michelotti, A; Milella, M; Papaldo, P; Pellegrini, M; Ricci, S; Ruggeri, EM; Salesi, N | 1 |
| Berstein, LM; Bozhok, AA; Dashyan, GA; Ivanov, VG; Kletzel, A; Melnikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Ziltsova, EK | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Gallagher, J; Habin, K; Winters, L | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Fabian, CJ | 1 |
| Perez, EA | 1 |
| Jahanzeb, M | 1 |
| Bershteĭn, LM; Bozhok, AA; Damenia, AO; Dashian, GA; Donskikh, RV; Ivanov, VG; Klettsel', AA; Kochetova, IA; Krivorot'ko, PV; Mel'nikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Tonuzov, EE; Voskresenskiĭ, DA; Zernov, KIu; Zhil'tsova, EK | 1 |
| Clack, G; Eastell, R; Finkelman, RD; Fraser, WD; Hannon, RA; Lakner, G; McCloskey, EV; Miyamoto, A | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Blackwell, KL; Herold, CI | 2 |
| Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Aapro, M | 1 |
| Cuzick, J | 1 |
| Pennery, E | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Fields, MM; Mellington, TE | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Nagykálnai, T | 1 |
| Chen, S; Lui, K; Masri, S; Phung, S; Wang, X; Ye, J; Zhou, D | 1 |
| Gibson, K; O'Bryant, CL | 1 |
| Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP | 1 |
| Al-Sukhun, S; Chollet, P; Durando, X; Ferriere, JP; Mouret-Reynier, MA; Nabholtz, JM; Van Praagh, I | 1 |
| Bershteĭn, LM; Danilova, MA; Gershfel'd, ED; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Poroshina, TE; Tsyrlina, TE; Turkevich, EA | 1 |
| Glück, S | 1 |
| Amir, E; Clemons, M; Cole, DE; Dowsett, M; Dranitsaris, G; Folkerd, E; Freedman, OC; Hanna, W; Kahn, H; O'Malley, F; Verma, S | 1 |
| Lazarus, P; Sun, D | 1 |
| Doyen, J; Ferrero, JM; Fontana, X; Italiano, A; Largillier, R; Thyss, A | 1 |
| Chen, S; Masri, S; Phung, S; Wang, X | 1 |
| Devine, S; Sedjo, RL | 1 |
| Amonkar, MM; Forbes, CA; Kessels, A; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Bertolini, E; Letho-Gyselinck, H; Prati, C; Wendling, D | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L | 1 |
| Batzler, A; Chapman, JA; Ellis, MJ; Flockhart, DA; Goetz, MP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Pater, J; Pritchard, KI; Rohrer, DC; Schaid, DJ; Shepherd, L; Stearns, V; Wang, L; Weinshilboum, RM | 1 |
| Tang, SC | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H | 2 |
| Doughty, JC | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA | 1 |
| Landherr, L; Mészáros, E; Nagykálnai, T | 1 |
| Buś-Kwaśnik, K; Ksycińska, H; Rudzki, PJ; Szlagowska, A | 1 |
| Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B | 1 |
| Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A | 1 |
| Glück, S; Gorouhi, F | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Alba Conejo, E; Bayo Calero, J; de la Cabeza Lomas Garrido, M; de la Haba Rodríguez, J; de Toro Salas, R; González Mancha, R; Martínez Guisado, A; Ruíz Borrego, M; Sánchez Muñoz, A | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Schmidt, C | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL | 1 |
| Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H | 1 |
| Burstein, HJ; Griggs, JJ | 1 |
| Carro, G; Harper, A; Hui, W; Lawton, J; Menas, P; Merkel, D | 1 |
| Bershteĭn, LM; Boiarkina, MP; Danilova, MA; Gershfel'd, ÉD; Khadzhimba, AS; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Turkevich, EA | 1 |
| Allred, DC; Babiera, GV; Ballman, K; Bose, R; Chang, LW; Chen, K; Crowder, R; Demeter, R; DeSchryver, K; Ding, L; Dooling, DJ; Du, F; Elhammali, A; Ellis, MJ; Esserman, L; Fulton, LL; Fulton, RS; Goiffon, RJ; Goldstein, TC; Guenther, JM; Harris, CC; Harrison, M; Hoog, J; Hunt, K; Kandoth, C; Koboldt, DC; Leitch, M; Ley, TJ; Lin, L; Lu, C; Luo, J; Maher, CA; Marcom, PK; Mardis, ER; Margenthaler, J; McDonald, S; McLellan, MD; McMichael, JF; Miller, CA; Ng, S; Oberkfell, B; Olson, J; Ota, D; Piwnica-Worms, D; Piwnica-Worms, H; Schierding, WS; Shen, D; Snider, J; Stuart, JM; Suman, VJ; Tao, Y; Unzeitig, G; Van Tine, BA; Vickery, TL; Wallis, JW; Watson, M; Weber, J; Wendl, MC; Wilson, RK | 1 |
| Brooks, JD; Dickler, MN; Goldfarb, SB; Jozefara, JE; King, V; Morris, EA; Nulsen, BF; Pike, MC; Sung, JS | 1 |
| Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K | 1 |
| Glück, S; Untch, M; von Minckwitz, G | 1 |
| Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R | 1 |
| Tung, N | 1 |
| Akiyoshi, T; Asayama, T; Hiura, S; Kato, H; Masuda, S; Ohtani, H; Okamoto, Y; Shimomura, Y | 1 |
| Hashigaki, S; Hiraoka, M; Iwata, H; Masuda, N; Morimoto, T; Nishizawa, Y; Noguchi, S; Ohno, S; Ohsumi, S; Rai, Y; Saeki, T; Sasano, H; Sato, Y | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Mehta, A; Tripathy, D | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Chlebowski, RT | 1 |
| Brufsky, A; Mathew, A | 1 |
| Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V | 1 |
| Arsav, V; Benderli Cihan, Y | 1 |
| Bowman, M; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Seluzicki, C; Xie, SX; Zee, J | 1 |
| Batzler, A; Carlson, EE; Chapman, JA; Ellis, MJ; Furukawa, Y; Goss, PE; Ingle, JN; Jenkins, GD; Khosla, S; Kubo, M; Liu, M; Nakamura, Y; Schaid, DJ; Shepherd, LE; Wang, L; Weinshilboum, RM | 1 |
| Olin, JL; St Pierre, M | 1 |
| Albertini, S; Kelly, E; Lu, CY; Vitry, A | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Benemei, S; Coppi, E; De Logu, F; Di Tommaso, MR; Fusi, C; Geppetti, P; Marone, IM; Materazzi, S; Minocci, D; Moneti, G; Nassini, R; Pieraccini, G; Susini, T; Trevisan, G; Tuccinardi, T | 1 |
| Budd, GT; Chapman, JA; Ellis, MJ; Goss, PE; Ingle, JN; Kundapur, J; Le Maitre, A; Liedke, PE; Ma, CX; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Stearns, V | 1 |
| Gradishar, WJ | 1 |
| Lanuti, M; Lerwill, MF; Moy, B; Rafferty, EA; Specht, MC | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P | 1 |
| Chatziralli, IP; Chrysikos, D; Ladas, I; Moschos, MM; Sergentanis, T; Zagouri, F; Zografos, G | 1 |
| Bevers, TB | 1 |
| Biggers, A; Charlson, JA; Kamaraju, S; Laud, PW; Neuner, JM; Pezzin, LE; Smallwood, AJ; Smith, EC; Wozniak, EM | 1 |
| Chang, CH; Chen, SJ; Liu, CY | 1 |
| Brodie, A; Guha, R; Jaiswal, AK; Khatri, R; Rassool, FV; Shah, P; Tomkinson, AE | 1 |
| Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E | 1 |
| Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
| Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M | 1 |
| Avenel-Audran, M; Cellier, P; Georgin-Mège, M; Le Corre, Y; Marchand, A; Martin, L | 1 |
| Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Amaral, C; Correia-da-Silva, G; Sobral, AF; Teixeira, N | 1 |
| Chapman, JA; Elliott, C; Gelmon, KA; Goss, PE; Ingle, JN; Muss, HB; Pritchard, KI; Shepherd, LE; Whelan, TJ | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Altinok, AY; Altug, T; Azria, D; Bese, NS; Ober, A; Ozsahin, EM; Sut, N; Yildirim, S | 1 |
| Niraula, S; Ocana, A | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Cohen, PR | 1 |
| Ali, SM; Budd, GT; Chapman, JW; Elliott, CR; Ellis, MJ; Garg, A; Goss, PE; Han, L; Ingle, JN; Leitzel, K; Lipton, A; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Agarwal, SK; Bartlett, J; Bongartz, T; Chapman, JW; Chen, B; Gelmon, K; Goss, PE; Hilsenbeck, SG; Ingle, JN; Kalari, KR; Niravath, P; Osborne, CK; Pritchard, K; Rimawi, MF; Shepherd, LE; Welschhans, RL | 1 |
| Vohora, D; Zameer, S | 1 |
| Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G | 1 |
| Deng, Y; Tian, W; Wu, M | 1 |
| Bufill, JA; Cella, D; Chapman, JW; Goss, PE; LaFrancis, IE; Mattar, BI; Nagargoje, GG; Nikcevich, DA; Schultz, WC; Shepherd, LE; Sledge, GW; Vemuri, R; Wagner, LI; Whelan, TJ; Zhao, F | 1 |
| Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C | 1 |
| Dirix, LY | 1 |
| Evans, DG; Howell, A; Howell, SJ | 1 |
| Chang, B; Fan, X; Jiang, X; Kariminia, S; Li, L; Li, Q; Li, T; Li, Y; Wu, S; Zhang, J | 1 |
| Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N | 1 |
| Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| DiNardo, D; Farkas, A; Merriam, S; Vanderberg, R | 1 |
| Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R | 1 |
| Petit, T | 1 |
| Fakolade, A; Fan, T | 1 |
| Jamal, QMS | 1 |
| Gui, L; Li, Q; Luo, Y; Sun, J; Wang, L; Wang, Q; Zhang, P; Zhang, S | 1 |
| Chen, C; Guan, J; Huang, X; Lin, Y; Mao, F; Shen, S; Sun, Q; Wang, C; Yao, R; Zhang, X; Zhao, J; Zhou, Y; Zhu, H | 1 |
| DiNome, ML; Ganz, PA; Graham, D | 1 |
| Banda, K; Fritzsche, D; Indorf, A; Miske, A | 1 |
| Barman, P; Cairns, J; Carlson, EE; Ellis, MJ; Gao, H; Goetz, MP; Goodnature, B; Goss, PE; Ingle, JN; Kalari, KR; Shepherd, LE; Wang, L; Weinshilboum, RM | 1 |
| Almeida, CF; Amaral, C; Augusto, TV; Correia-da-Silva, G; Teixeira, N | 1 |
| Boughey, JC; Ellis, MJ; Hunt, KK; Leitch, AM; Meric-Bernstam, F; Olson, J; Suman, VJ; Unzeitig, G; Wingate, HF | 1 |
111 review(s) available for anastrozole and aromasil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen | 2022 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Estrone; Female; Humans; Letrozole; Nitriles; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Fadrozole; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2000 |
[Preclinical evaluation of aromatase inhibitors antitumor activity].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Models, Animal; Nitriles; Rats; Structure-Activity Relationship; Triazoles | 2000 |
[Aromatase inhibitors: pharmacological aspects].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Survival Analysis; Treatment Outcome; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles | 2002 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Progestins; Receptors, Estrogen; Treatment Outcome; Triazoles | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Premenopause; Triazoles | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Letrozole; Lipids; Nitriles; Postmenopause; Triazoles | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2004 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Humans; Letrozole; Molecular Structure; Nitriles; Triazoles | 2005 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Menopause; Nitriles; Triazoles | 2004 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2005 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Nitriles; Research Design; Tamoxifen; Triazoles | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy; Estrogens; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Life Style; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Population Surveillance; Risk Factors; Triazoles | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Monitoring; Female; Humans; Musculoskeletal Diseases; Nitriles; Nurse's Role; Nursing Assessment; Nursing Research; Oncology Nursing; Pain; Pain Management; Pain Measurement; Patient Care Planning; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Receptors, Estrogen; Treatment Outcome; Triazoles | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Triazoles | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cancer; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Medication Adherence; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Risk Factors; Triazoles | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Nitriles; Postmenopause; Survival Analysis; Triazoles | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Detection of Cancer; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease Management; Disease Progression; Drug Therapy, Combination; Female; Geriatric Assessment; Health Status; Humans; Letrozole; Life Expectancy; Nitriles; Prognosis; Quality of Life; Treatment Outcome; Triazoles | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Invasiveness; Nitriles; Postmenopause; Risk; Triazoles | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles | 2016 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2018 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene | 2020 |
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate | 2019 |
38 trial(s) available for anastrozole and aromasil
| Article | Year |
|---|---|
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2005 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Triazoles | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2007 |
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
Topics: Adrenal Glands; Alkaline Phosphatase; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Body Mass Index; Bone and Bones; Bone Remodeling; Bone Resorption; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Triazoles | 2007 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; Breast Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nitriles; Pilot Projects; Postmenopause; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles | 2009 |
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Drug Administration Schedule; Estradiol; Female; Humans; Ki-67 Antigen; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2010 |
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Gene Expression; Genome-Wide Association Study; Humans; Interleukin-17; Linkage Disequilibrium; Musculoskeletal Diseases; Nitriles; Pharmacogenetics; Polymorphism, Single Nucleotide; Triazoles | 2010 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides | 2011 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Triazoles | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Testosterone; Triazoles | 2011 |
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2012 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; History, 18th Century; Hot Flashes; Humans; Hypercholesterolemia; Kaplan-Meier Estimate; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Time Factors; Treatment Outcome; Triazoles | 2013 |
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone and Bones; Breast Neoplasms; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Grading; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bones of Lower Extremity; Breast Neoplasms; Calcium; Canada; Chemotherapy, Adjuvant; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radiography; Time Factors; Treatment Outcome; Triazoles; United States; Vitamin D | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depression; Electroacupuncture; Fatigue; Female; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Sleep Wake Disorders; Stress, Psychological; Treatment Outcome; Triazoles | 2014 |
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Female; Gene-Environment Interaction; Genome-Wide Association Study; Genotype; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporotic Fractures; Polymorphism, Single Nucleotide; Triazoles | 2014 |
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hot Flashes; Humans; Kaplan-Meier Estimate; Middle Aged; Musculoskeletal System; Nitriles; Triazoles; Vasomotor System | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles | 2015 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Potentials, Visual; Female; Humans; Letrozole; Middle Aged; Nerve Fibers; Nitriles; Optic Nerve; Retina; Tomography, Optical Coherence; Triazoles; Visual Acuity | 2016 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Comorbidity; Female; Humans; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Treatment Outcome; Triazoles | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Male; Mastectomy; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis, Postmenopausal; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Treatment Outcome; Triazoles | 2017 |
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Interleukin-1beta; Mastectomy; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Vitamin D | 2018 |
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Treatment Outcome; Triazoles | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2018 |
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method | 2019 |
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Young Adult | 2020 |
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
Topics: Anastrozole; Androstadienes; Antigens, CD; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Epithelial-Mesenchymal Transition; Female; Humans; Lectins, C-Type; Minor Histocompatibility Antigens; Neoplasm Staging; Patient Selection; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Treatment Outcome | 2021 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Mastectomy; Neoadjuvant Therapy; Postmenopause; Receptors, Estrogen | 2023 |
91 other study(ies) available for anastrozole and aromasil
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogens; Estrone; Female; Fibroblasts; Humans; In Vitro Techniques; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Comparison of in vitro exemestane activity versus other antiaromatase agents.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Choriocarcinoma; Female; Humans; Nitriles; Triazoles; Tumor Cells, Cultured | 2000 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Middle Aged; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2003 |
[Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Postmenopause; Triazoles | 2004 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Confidence Intervals; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2005 |
[Advance and current status of exemestane and androstadienes in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Nitriles; Postmenopause; Triazoles | 2005 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2005 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Humans; Male; Nitriles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection; Tandem Mass Spectrometry; Triazoles | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Humans; Letrozole; Leuprolide; Lung Neoplasms; Lymphatic Metastasis; Male; Mastectomy, Modified Radical; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Nitriles; Remission Induction; Tamoxifen; Triazoles | 2007 |
[Clinical study of aromatase inhibitors in advanced breast cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2007 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Rate; Triazoles | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Profiling; Humans; Microarray Analysis; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 2009 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis; Retrospective Studies; Triazoles | 2008 |
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Endometrial Neoplasms; Estradiol; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Receptors, Progesterone; Time Factors; Treatment Outcome; Triazoles | 2009 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Letrozole; Nitriles; Triazoles; Vitamin D | 2010 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma; Estradiol; Humans; Letrozole; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Testosterone; Treatment Outcome; Triazoles | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2010 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Databases as Topic; Delivery of Health Care; Drug Costs; Female; Health Knowledge, Attitudes, Practice; Humans; Insurance, Health; Letrozole; Logistic Models; Medication Adherence; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; Triazoles; United States | 2011 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2011 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Middle Aged; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2010 |
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chromosome Mapping; Chromosomes, Human, Pair 14; Clinical Trials, Phase III as Topic; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Logistic Models; Middle Aged; Musculoskeletal System; Neoplasm Staging; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Proto-Oncogene Proteins; Randomized Controlled Trials as Topic; Receptors, Interleukin-17; Retrospective Studies; Severity of Illness Index; Triazoles | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Chromatography, Liquid; Humans; Linear Models; Nitriles; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2012 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Incidence; Neoplasms, Hormone-Dependent; Nitriles; Outpatients; Retrospective Studies; Triazoles | 2012 |
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Endometrial Neoplasms; Female; Glucose; Humans; Hypoglycemic Agents; Ki-67 Antigen; Letrozole; Metformin; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Nitriles; Treatment Outcome; Triazoles | 2011 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; DNA Repair; Exome; Exons; Female; Genetic Variation; Genome, Human; Humans; Letrozole; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 1; Mutation; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Letrozole; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Retrospective Studies; Subtraction Technique; Triazoles | 2012 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Blepharitis; Breast Neoplasms; Conjunctival Diseases; Dry Eye Syndromes; Female; Humans; Keratitis; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Retrospective Studies; Triazoles; Vision Disorders | 2013 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2013 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Diphosphonates; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Triazoles | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2013 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
The bone substudy of MA.27: does bone make a difference?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2014 |
The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats.
Topics: Anastrozole; Androstadienes; Animals; Antibodies, Monoclonal; Aromatase Inhibitors; Combined Modality Therapy; Drug Administration Schedule; Female; Heart; Humans; Letrozole; Nitriles; Radiotherapy; Rats; Rats, Wistar; Trastuzumab; Triazoles; Tumor Protein, Translationally-Controlled 1 | 2014 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.
Topics: Anastrozole; Androstadienes; Animals; Aromatase Inhibitors; Behavior, Animal; Calcium; Calcium Channels; Cysteine; HEK293 Cells; Humans; Inflammation; Letrozole; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuropeptides; Nitriles; Pain; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Steroids; Transient Receptor Potential Channels; Triazoles; TRPA1 Cation Channel; TRPC Cation Channels | 2014 |
No pain, no gain: a fallacy so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Musculoskeletal System; Nitriles; Triazoles; Vasomotor System | 2015 |
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Mastectomy, Segmental; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Triazoles | 2015 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Costs; Drugs, Generic; Evaluation Studies as Topic; Female; Humans; Letrozole; Medicare; Medication Adherence; Nitriles; Non-Randomized Controlled Trials as Topic; Poverty; Triazoles; United States | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Letrozole; MCF-7 Cells; Molecular Structure; NF-E2-Related Factor 2; Nitriles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Triazoles; Ubiquitination | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Hormones; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2015 |
Exemestane-induced radiation recall dermatitis and morbilliform rash.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Eruptions; Eosinophilia; Epidermis; Exanthema; Female; Humans; Nitriles; Radiodermatitis; Radiotherapy, Adjuvant; Triazoles; Withholding Treatment | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiotherapy; Rats; Rats, Wistar; Tamoxifen; Triazoles | 2016 |
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
Effect of aromatase inhibitors on learning and memory and modulation of hippocampal dickkopf-1 and sclerostin in female mice.
Topics: Adaptor Proteins, Signal Transducing; Anastrozole; Androstadienes; Animals; Aromatase Inhibitors; Cognition; Female; Glycoproteins; Hippocampus; Intercellular Signaling Peptides and Proteins; Letrozole; Maze Learning; Memory; Mice; Nitriles; Triazoles; Wnt Signaling Pathway | 2017 |
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; China; Female; Humans; Letrozole; Lipid Metabolism; Lipids; Middle Aged; Postmenopause; Retrospective Studies | 2018 |
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Reported Outcome Measures; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome | 2018 |
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds | 2019 |
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Making, Shared; Female; Humans; Middle Aged; Physician-Patient Relations; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Medication Use to Reduce Risk of Breast Cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medication Adherence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2020 |
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Computer Simulation; DNA Topoisomerases, Type II; Female; Humans; Letrozole; Protein Conformation | 2020 |
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Humans; Letrozole; Postmenopause; Prospective Studies | 2020 |
Breast Cancer Risk-Reducing Medications.
Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Exemestane induced cholestatic liver injury - A case report.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cholestasis; Female; Humans | 2021 |
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Topics: Anastrozole; Androstadienes; Apoptosis; Aromatase Inhibitors; Autophagy; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Cyclins; Early Growth Response Protein 3; Estrogens; Female; Gene Expression Regulation, Neoplastic; Hormones; Humans; Letrozole; Receptors, Androgen; Receptors, Estrogen; Signal Transduction; Tumor Suppressor Proteins | 2021 |